Sarepta Therapeutics Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Sarepta Therapeutics Bundle
What is included in the product
Detailed Word Document
Sarepta's BCG matrix shows investment prioritization, analyzing its products' market growth and share positions.
Customizable Excel Spreadsheet
Sarepta's BCG Matrix streamlines complex data with a clear quadrant view, delivering a concise strategic overview.
Delivered as Shown
Sarepta Therapeutics BCG Matrix
The Sarepta Therapeutics BCG Matrix preview displays the complete document you'll receive after purchase. This is the final, fully editable version—ready for immediate strategic application. No hidden content or watermarks; just the finished report. Download and immediately integrate it into your business analysis.
BCG Matrix Template
Download Your Competitive Advantage
Sarepta Therapeutics' diverse portfolio includes groundbreaking gene therapies, each at a different stage of market presence. Their Exondys 51 represents a mature product, while other treatments are still emerging. This BCG Matrix preview gives a glimpse into where each product sits—Stars, Cash Cows, or Question Marks. Discover the strategic implications of their product mix.
Get the full BCG Matrix report to uncover detailed quadrant placements, data-backed recommendations, and a roadmap to smart investment and product decisions.
Stars
ELEVIDYS (delandistrogene moxeparvovec-rokl)
ELEVIDYS, Sarepta's gene therapy for Duchenne muscular dystrophy (DMD), is a "star." The therapy brought in $384.2 million in net product revenue in Q4 2024. Its broad label covers most Duchenne patients, fueling high demand. ELEVIDYS is set to boost Sarepta's 2025 revenue significantly.
RNA-based PMOs (EXONDYS 51, VYONDYS 53, AMONDYS 45)
Sarepta's RNA-based PMOs (EXONDYS 51, VYONDYS 53, AMONDYS 45) remain a star. These therapies generated $254.0 million in Q4 2024 revenue and $967.2 million for the full year. They continue to serve specific DMD patient populations. Their market presence remains strong alongside ELEVIDYS.
Limb-girdle Muscular Dystrophy (LGMD) Pipeline
Sarepta's LGMD pipeline is poised to be a Star, with significant growth potential. The company is advancing gene therapy programs for various LGMD subtypes. SRP-9003, targeting LGMD 2B/R2, is on track for a BLA submission to the FDA in the second half of 2025. This highlights Sarepta's commitment to addressing unmet medical needs.
siRNA Programs (Arrowhead Collaboration)
Sarepta's partnership with Arrowhead Pharmaceuticals for siRNA programs is a smart move into a promising field. This collaboration gives Sarepta a wider range of clinical and preclinical programs. These siRNA programs could become major successes, with possible blockbuster potential in the late 2020s. The market for RNA-based therapeutics is expected to reach $44.1 billion by 2028, showing significant growth potential.
- Strategic Expansion: Sarepta diversifies its pipeline with siRNA programs.
- Market Opportunity: RNA therapeutics market is set to grow significantly by 2028.
- Collaboration Benefits: Access to multiple clinical and preclinical programs.
- Future Potential: Anticipated blockbuster opportunities in 2028 and 2029.
Financial Performance & Growth
Sarepta Therapeutics shines as a Star due to its robust financial performance. The company's net product revenues surged by 75% in Q4 2024, reaching $638.2 million. This strong growth, combined with GAAP net income of $159.0 million and non-GAAP net income of $206.0 million, showcases its potential.
- Q4 2024 Net Product Revenues: $638.2 million
- Q4 2024 GAAP Net Income: $159.0 million
- Q4 2024 Non-GAAP Net Income: $206.0 million
Sarepta's Revenue Soars: ELEVIDYS and PMOs Lead the Way!
Sarepta's ELEVIDYS and RNA-based PMOs are key Stars. ELEVIDYS had $384.2M in Q4 2024 revenue, with the PMOs at $254.0M. LGMD pipeline also shows Star potential with SRP-9003 BLA submission in 2025. Sarepta's net product revenues rose to $638.2M in Q4 2024.
| Therapy | Q4 2024 Revenue | Notes |
|---|---|---|
| ELEVIDYS | $384.2M | Gene therapy for DMD. |
| PMOs | $254.0M | RNA-based therapies. |
| LGMD Pipeline | N/A | BLA submission planned. |
Cash Cows
EXONDYS 51
EXONDYS 51, an established DMD therapy, is a cash cow for Sarepta. It uses exon-skipping tech and PMO chemistry, ensuring steady sales. Despite competition, it generates stable revenue. In Q3 2024, EXONDYS 51 sales were $89.4 million. This solidifies its cash cow status.
VYONDYS 53
VYONDYS 53, a PMO-based therapy from Sarepta, targets a specific exon mutation in DMD patients, bolstering cash flow. Its established market position and dedicated patient base, like EXONDYS 51, ensure revenue. In 2024, VYONDYS 53 generated approximately $400 million in sales. While growth is moderate, it's a dependable revenue source for Sarepta.
AMONDYS 45
AMONDYS 45 is a PMO-based therapy for DMD like EXONDYS 51 and VYONDYS 53. It targets a specific exon mutation, offering Sarepta consistent revenue. AMONDYS 45 leverages Sarepta's infrastructure and market access. It contributes to Sarepta's financial stability, with 2024 sales expected to be robust. The drug is a steady performer, even if growth is moderate.
Duchenne Muscular Dystrophy (DMD) Franchise
Sarepta's DMD franchise, including EXONDYS 51, VYONDYS 53, and AMONDYS 45, is a cash cow, consistently generating revenue. The franchise benefits from a strong market presence and reputation. Sarepta has commercialized four approved DMD products: EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS. This established position provides a stable financial base.
- EXONDYS 51, a key product, saw $198.4 million in 2023.
- VYONDYS 53 generated $243.1 million in 2023.
- AMONDYS 45 brought in $224.7 million in 2023.
- ELEVIDYS, the newest addition, is expected to grow significantly.
Manufacturing Capabilities
Sarepta's manufacturing prowess solidifies its cash cow status. Their established processes for PMO-based therapies ensure reliable production and supply, meeting market needs. Strategic partnerships boost efficiency and profitability. This operational strength fortifies Sarepta's financial standing.
- In 2024, Sarepta's revenue reached approximately $1.2 billion, driven by their established therapies.
- Sarepta has invested heavily in expanding manufacturing capacity.
- Their manufacturing efficiency allows for competitive pricing and healthy profit margins.
Sarepta's DMD Therapies: Revenue Surge in 2024!
Sarepta's cash cows include EXONDYS 51, VYONDYS 53, and AMONDYS 45, consistently generating revenue from DMD therapies. These products benefit from established market positions and Sarepta's manufacturing strengths. In 2024, Sarepta's revenue hit around $1.2 billion, with these therapies contributing significantly.
| Product | 2023 Revenue (USD millions) | 2024 Revenue (Estimated USD millions) |
|---|---|---|
| EXONDYS 51 | $198.4 | $350 |
| VYONDYS 53 | $243.1 | $400 |
| AMONDYS 45 | $224.7 | $300 |
Dogs
Early-Stage Research Programs (pre-clinical)
Some of Sarepta's early-stage programs, still pre-clinical, fit the "Dog" category. These programs currently operate in low-growth markets. Their market share is also low, with uncertain near-term returns. Sarepta allocated approximately $1.8 billion to R&D in 2023, including these high-risk ventures. These programs need continued investment despite uncertain outcomes.
Strategic Investments with Limited Returns
Strategic investments with limited returns fit the "Dogs" quadrant. These investments fail to generate significant revenue or support core objectives. Sarepta Therapeutics faced a one-time impairment of a strategic investment in 2023. This action reflects the challenges in this area, potentially impacting future returns.
Programs Facing Regulatory Hurdles
Sarepta's "Dogs" include programs with regulatory challenges. A clinical hold by the EMA on Elevidys trials creates uncertainty. This could limit market access and affect stock performance. In 2024, Sarepta's stock faced volatility due to these regulatory issues. The EMA's decision directly impacts Elevidys's future.
Therapies with Limited Patient Populations
Therapies for small patient populations, or niche markets, can be "Dogs" due to limited revenue potential. These address unmet needs, but may not justify continued investment. Sarepta focuses on rare disease therapies. For example, in 2024, Sarepta's revenue was $1.2 billion. These therapies face high development costs.
- Low Revenue Potential
- Unmet Medical Needs
- Rare Disease Focus
- High Development Costs
Programs Outside Core Focus Areas
Sarepta Therapeutics' programs outside its core focus, like those not related to DMD and LGMDs, might be considered "Dogs" in a BCG matrix. These ventures often lack synergy with existing expertise, potentially leading to inefficient resource allocation. Such programs could demand substantial investments in unfamiliar territories, diluting focus. This strategic assessment is crucial for optimizing Sarepta's portfolio and resource deployment. In 2024, Sarepta's R&D expenses were significant, highlighting the need for careful program prioritization.
- Lack of Synergy: Programs not aligning with Sarepta's core expertise.
- High Investment Needs: Requiring significant financial resources.
- Resource Dilution: Potentially diverting from key areas.
- Strategic Reassessment: Critical for portfolio optimization.
Sarepta's Risky Bets: Early-Stage Programs Under Scrutiny
Sarepta's "Dogs" include early-stage, pre-clinical programs with low market share and uncertain returns, representing a significant portion of its R&D spend, which was $1.8B in 2023. These ventures face regulatory hurdles and may address niche markets with limited revenue, as seen with Elevidys's challenges. Programs outside Sarepta's core focus also fall into this category, requiring strategic reassessment.
| Category | Characteristics | Financial Impact (2024) |
|---|---|---|
| Early-Stage Programs | Pre-clinical, low market share | High R&D costs (approx. $1.8B in 2023) |
| Regulatory Challenges | Clinical holds, market access limits | Stock volatility |
| Niche Markets | Limited revenue potential | $1.2B in revenue |
Question Marks
SRP-9003 for LGMD2E/R4
SRP-9003 is a gene therapy targeting LGMD2E/R4, classified as a Question Mark in Sarepta's BCG matrix. It's in a high-growth market but has a low market share currently. Sarepta plans to submit a BLA to the FDA in the second half of 2025. Data from the EMERGENE trial are anticipated in the first half of 2025, which will be critical for its future. The global market for gene therapy is projected to reach $11.6 billion by 2028.
SRP-9004 for LGMD type 2D/R3
SRP-9004, a gene therapy for LGMD type 2D/R3, sits as a Question Mark for Sarepta. It targets a high-growth market but currently holds a low market share. The DISCOVERY study, a phase 1 proof-of-concept, has finished enrollment and dosing. DISCOVERY assesses safety and alpha-sarcoglycan protein expression.
SRP-9005 for LGMD type 2C/R5
SRP-9005, Sarepta's gene therapy for LGMD type 2C/R5, is a Question Mark. It targets a high-growth market but currently holds a low market share. Sarepta received FDA clearance to proceed with dosing in the COMPASS study. The LGMD market is estimated to reach significant value, presenting growth opportunities for SRP-9005.
siRNA Programs for CNS Disorders
Sarepta Therapeutics' siRNA programs for CNS disorders, stemming from the Arrowhead collaboration, are positioned as "Stars" in its BCG matrix due to their high growth potential and relatively low current market share. These programs target neurodegenerative diseases and other CNS conditions, marking a new therapeutic area for Sarepta, expanding its focus beyond its core muscle-related treatments. The most advanced candidate, ARO-ATXN2, is undergoing Phase I trials for spinocerebellar ataxia type 2 (SCA2), a debilitating neurodegenerative disease. Sarepta's investment in these programs is driven by the significant unmet medical needs in CNS disorders and the potential for substantial market growth.
- ARO-ATXN2, the lead CNS candidate, is in Phase I trials for SCA2.
- These programs represent a strategic expansion into the CNS therapeutic area.
- Sarepta aims to capitalize on the high growth potential of the CNS market.
- The Arrowhead collaboration provides access to siRNA technology.
Gene Editing Programs
Sarepta Therapeutics' gene editing programs are categorized as question marks in the BCG matrix. These programs are in their early stages, indicating high potential but also uncertain outcomes. Sarepta is utilizing advanced gene editing technologies to create new therapies for genetic diseases. Due to low market share, these programs face high demands and low returns.
- Early-stage development signifies high risk and uncertainty.
- Focus on novel therapies for genetic diseases.
- Low market share contributes to lower returns initially.
- Gene editing programs are resource-intensive.
Sarepta's Early-Stage Pipeline: High Risk, High Reward
Question Marks represent Sarepta's early-stage products. They operate in high-growth markets but have low current market share. This category includes gene therapies and gene editing programs, with high risk. Sarepta's R&D expenses were $274.7 million in Q3 2024.
| Therapeutic Area | Product Type | Status |
|---|---|---|
| LGMD | Gene Therapy | Phase 1-3 trials |
| CNS | siRNA | Phase 1 trials |
| Genetic Diseases | Gene Editing | Early Stage |
BCG Matrix Data Sources
Sarepta's BCG Matrix uses reliable sources such as financial filings, market analyses, and expert evaluations, providing accurate strategic insights.
